Cov khoom

Fluorouracil antineoplastic tshuaj yog prodrugs ntawm fluorouracil.Lub thymidine phosphorylase uas muaj nyob rau hauv cov qog nqaij hlav ua rau nws hloov mus rau hauv fluorochemicalbook uracil hauv cov qog, yog li ua rau muaj kev tiv thaiv qog.Nws cov tshuaj tiv thaiv qog tshwj xeeb yog muaj zog, thiab nws cov toxicity tsawg.Clinically siv rau mob qog noj ntshav, mob qog noj ntshav, mob qog noj ntshav, mob cancer mis, tus nqi tso tawm tuaj yeem ncav cuag ntau dua 30%.

Kev ua tau zoo ntawm kev siv tshuaj tua kab mob rau kev nthuav tawm peritoneal ntawm kev mob plab hnyuv tseem tsis meej.Kev ua tau zoo ntawm paclitaxel txhua lub limtiam hauv kev sib xyaw nrog doxifluridine (5'-DFUR) hauv cov neeg mob qog noj ntshav hauv plab nrog cov ascites malignant ascites tau raug soj ntsuam. Cov neeg mob uas tau kuaj pom tias mob plab hnyuv nrog ascites tau tsim nyog.Cov kev kho mob muaj paclitaxel intravenously (iv) noj ntawm 80 mg / m (2) nyob rau hnub 1, 8 thiab 15 txhua 4 lub lis piam, thiab doxifluridine muab qhov ncauj ntawm 533 mg / m (2) hnub 1-5 txhua lub lis piam.Cov lus teb rau cov neeg mob ascites tau txiav txim siab raws li Japanese Kev faib tawm ntawm Gastric Carcinoma.Tsis tas li ntawd, qhov concentration ntawm paclitaxel hauv cov ascites tau ntsuas.Neeg plaub tus neeg mob tau tshawb xyuas.Cov lus teb tus nqi (RR) yog 41.7%, suav nrog kev tso tawm kom tiav (CR) thiab kev tso tawm ib nrab (PR) hauv 4 thiab 6 tus neeg mob, feem.Cov concentration ntawm paclitaxel nyob rau hauv cov ascites tau khaws cia ntawm 0.01 μM thiab 0.05 μM txog 72 teev.Qhov nruab nrab tag nrho cov ciaj sia taus (OS) yog 215 hnub, thiab 1-xyoo ciaj sia taus yog 29.2%.Tsis muaj cov tshuaj toxicity hnyav heev.Lub lim tiam paclitaxel ua ke nrog doxifluridine yog qhov zoo rau cov neeg mob qog noj ntshav nrog cov ascites malignant ascites nrog rau qhov pom zoo toxicity profile.